» Articles » PMID: 38066886

Where Have All the Platelets Gone? HIT, DIC, or Something Else?

Overview
Authors
Affiliations
Soon will be listed here.
Abstract

Thrombocytopenia in ill children is common; accurately diagnosing the underlying etiology is challenging and essential for appropriate management. Triggers for accelerated consumption of platelets are numerous; common downstream mechanisms of clearance include platelet trapping in microvascular thrombi, phagocytosis, and platelet activation. Thrombocytopenia with microangiopathic hemolytic anemia (MAHA) is frequently due to disseminated intravascular coagulation. Thrombotic microangiopathy (TMA) is a subgroup of MAHA. Specific TMA syndromes include thrombotic thrombocytopenic purpura, complement-mediated TMA (CM-TMA), and Shiga toxin-mediated hemolytic uremic syndrome. Isolated thrombocytopenia is characteristic of immune thrombocytopenia; however, concomitant cytopenias are frequent in critically ill patients, making the diagnosis difficult. Immune thrombocytopenia with large vessel thrombosis is a feature of heparin-induced thrombocytopenia and antiphospholipid antibody syndrome. In addition, thrombocytopenia is common with macrophage activation, which is characteristic of hemophagocytic lymphohistiocytosis. While thrombocytopenia in ill patients can be driven by hypoproliferative processes such as myelosuppression and/or bone marrow failure, this review will focus on consumptive thrombocytopenia due to immune and nonimmune causes.

Citing Articles

Approaching Thrombospondin-1 as a Potential Target for Mesenchymal Stromal Cells to Support Liver Regeneration after Partial Hepatectomy in Mouse and Humans.

Tietze L, Christ M, Yu J, Stock P, Nickel S, Schulze A Cells. 2024; 13(6.

PMID: 38534373 PMC: 10969617. DOI: 10.3390/cells13060529.

References
1.
Reese J, Muthurajah D, Kremer Hovinga J, Vesely S, Terrell D, George J . Children and adults with thrombotic thrombocytopenic purpura associated with severe, acquired Adamts13 deficiency: comparison of incidence, demographic and clinical features. Pediatr Blood Cancer. 2013; 60(10):1676-82. DOI: 10.1002/pbc.24612. View

2.
Siddiqui A, Journeycake J, Borogovac A, George J . Recognizing and managing hereditary and acquired thrombotic thrombocytopenic purpura in infants and children. Pediatr Blood Cancer. 2021; 68(5):e28949. DOI: 10.1002/pbc.28949. View

3.
Cuker A, Arepally G, Chong B, Cines D, Greinacher A, Gruel Y . American Society of Hematology 2018 guidelines for management of venous thromboembolism: heparin-induced thrombocytopenia. Blood Adv. 2018; 2(22):3360-3392. PMC: 6258919. DOI: 10.1182/bloodadvances.2018024489. View

4.
Avila L, Amiri N, Yenson P, Khan S, Zavareh Z, Chan A . Heparin-Induced Thrombocytopenia in a Pediatric Population: Implications for Clinical Probability Scores and Testing. J Pediatr. 2020; 226:167-172.e2. DOI: 10.1016/j.jpeds.2020.06.081. View

5.
Taylor Jr F, Toh C, Hoots W, Wada H, Levi M . Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation. Thromb Haemost. 2002; 86(5):1327-30. View